Novo to Debut Real-World Wegovy vs Resmetirom MASH Data at AASLD 2025
Novo Nordisk will present a real-world comparison of semaglutide 2.4 mg (the active ingredient in Wegovy) against resmetirom in adults with MASH at The Liver Meeting, the American Association for the Study of Liver Diseases (AASLD) congress in Denver on 5–9 November, according to a company release dated 28 October. The study, called PLATINUM-Truveta, draws on de-identified electronic health records rather than a randomized trial, and the underlying numbers have not yet been disclosed publicly. This is a real-world evidence readout comparing a GLP-1 receptor agonist with a thyroid hormone receptor-beta agonist in metabolic liver disease — a comparison that peptide therapy clinics, telehealth operators and research-peptide suppliers will be watching closely.
The nut graf: MASH is a silent, progressive liver disease that Novo says affects more than 250 million people worldwide, with nearly 90% undiagnosed. Because semaglutide sits at the center of the GLP-1 peptide boom that now underpins much of the peptide therapy and compounding supply chain, any head-to-head signal — even an observational one — feeds directly into how clinics, prescribers and suppliers frame GLP-1 peptides in metabolic care.
What Novo will actually present in Denver
Novo says it is bringing 12 new abstracts to AASLD. The headline item is poster 2461, scheduled for 6 November, which Novo says has been named a Poster of Distinction — a designation reserved for roughly the top 10% of submissions. The poster compares semaglutide 2.4 mg with resmetirom in people with MASH using records from 30 US health systems covering June 2021 through March 2026.
According to the release, the PLATINUM-Truveta cohort includes 2,873 adults who started semaglutide and 2,285 who started resmetirom. Researchers tracked changes at three and six months across liver enzymes (ALT and AST), body weight, HbA1c, platelets, triglycerides, HDL and LDL. A sibling study, RHODIUM-2, compares 2,479 people who started semaglutide 2.4 mg with 70,702 who did not, at 3, 6 and 12 months.
Also on the schedule: a post-hoc analysis from the phase 3 ESSENCE trial, which enrolled 1,197 adults with MASH and moderate-to-advanced liver scarring (two-thirds on semaglutide 2.4 mg, the rest on placebo, for 240 weeks). The new angle is an oral presentation on 8 November examining participants with a BMI below 27. Novo describes this as hypothesis-generating. Four presentations cover efruxifermin, an investigational agent, including an AI-based analysis of the SYMMETRY phase 2b trial in compensated MASH cirrhosis.
Key numbers behind the AASLD 2025 abstracts
| Study / item | Design | Population | Timing at AASLD |
|---|---|---|---|
| PLATINUM-Truveta (poster 2461) | Real-world EHR comparison, semaglutide 2.4 mg vs resmetirom | 2,873 semaglutide; 2,285 resmetirom; 30 US health systems, Jun 2021–Mar 2026 | 6 November; Poster of Distinction |
| RHODIUM-2 | Real-world comparison, semaglutide 2.4 mg vs no semaglutide | 2,479 treated; 70,702 untreated | 3, 6 and 12-month checks |
| ESSENCE post-hoc (BMI <27) | Phase 3 post-hoc analysis | 1,197 adults with MASH and moderate-to-advanced scarring | Oral presentation, 8 November |
| SYMMETRY (efruxifermin) | Phase 2b, AI-based analysis | Compensated MASH cirrhosis | 8 November |
Why this matters for peptide therapy and GLP-1 research
Semaglutide is the reference GLP-1 receptor agonist in the current metabolic medicine cycle, and Wegovy holds FDA accelerated approval for MASH with moderate-to-advanced scarring (but not cirrhosis). That accelerated approval may depend on a confirmatory trial; ESSENCE part two, which tracks liver-related clinical events, is still running. A Boxed Warning for possible thyroid tumors also applies. For peptide therapy clinics and telehealth platforms, the practical question is not whether semaglutide “works” in MASH — that is being tested in randomized trials — but whether real-world records show divergence from resmetirom in routine care.
Industry observers note that observational comparisons of this kind are hypothesis-shaping, not confirmatory. Novo itself flags that patients were not randomized, received whichever drug they got in routine care, and that the team used statistical weighting to balance groups, counted only people still on treatment at each check, and excluded anyone with cirrhosis. Records can contain coding errors, follow-up was short, and unmeasured confounders may remain. The available evidence does not yet establish causality from PLATINUM-Truveta; it can only suggest associations.
For research-peptide businesses and suppliers, the readout matters at the level of demand narrative. GLP-1 peptides already dominate metabolic research and clinic procurement discussions; a liver-specific signal could widen the clinical conversation from weight management toward hepatic endpoints. That, in turn, affects how clinics document rationale, how compounding pharmacies field questions, and how suppliers of peptide APIs and finished formats position their catalogs. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
The supply-chain and clinic angle
Semaglutide is a synthetic peptide produced through solid-phase peptide synthesis and, in finished form, supplied as a vial, dual-chamber cartridge or prefilled injection pen depending on the product and market. The AASLD abstracts do not change any of that, but they do shape demand signals that ripple through the chain: API sourcing, fill-finish capacity, container closure systems, cold-chain logistics and batch documentation.
Clinic operators evaluating GLP-1 peptide offerings should keep several distinctions clear. An FDA-approved medicine, a compounded drug prepared under specific legal conditions, and a research-use-only peptide are three different regulatory categories. Research peptides are supplied for laboratory use and are not authorized treatments; a certificate of analysis reports specified analytical results for a batch but does not establish clinical safety, sterility for a particular use, or regulatory approval. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
On the quality side, buyers in this space increasingly ask for batch-specific COAs, HPLC and LC-MS data, impurity profiles and traceability records — the same documentation standards that pharmaceutical buyers request from peptide API manufacturers. None of that documentation substitutes for clinical evidence, and none of the AASLD data changes a product’s approval status.
What remains uncertain
The central uncertainty is simple: nobody outside Novo has seen the PLATINUM-Truveta numbers. The 28 October release describes who is presenting what and when, not results. Until the poster goes up on 6 November, any claim about how semaglutide compared with resmetirom in these records is speculation.
Beyond the numbers, several structural limits apply. Real-world EHR analyses cannot pin down causation. The follow-up windows of three and six months are short for a disease that progresses over years. Excluding patients with cirrhosis narrows the generalizable population. And the ESSENCE BMI-below-27 analysis is post-hoc, meaning the question was asked after the data were collected — useful as a lead, not as proof.
Regulatory questions also remain open. Wegovy’s accelerated approval in MASH hinges on confirmatory evidence, and the clinical-event readout from ESSENCE part two will be the decisive input. Nothing presented at AASLD substitutes for that trial.
What comes next
Watch three things after the congress. First, the PLATINUM-Truveta poster itself: which endpoints moved, by how much, and with what confidence intervals. Second, the RHODIUM-2 comparison, which uses a far larger untreated cohort and could inform how clinics think about untreated disease trajectories. Third, the ESSENCE post-hoc signal in leaner patients, which — if it holds — could shift how MASH is framed beyond obesity-centric models.
For the peptide therapy industry, the practical takeaway is to separate evidence tiers. Randomized trial data, real-world observational data, post-hoc analyses and in-vitro or animal findings carry different weight, and none of them should be presented to patients as proven efficacy beyond what regulators have reviewed. Clinics and telehealth operators should continue to emphasize prescription requirements and medical supervision, and suppliers should keep documentation and traceability front and center. 本篇新闻稿由PeptideSCM的记者David根据PeptideDDP的业务经理Sarah提供的新闻线索结合互联网公开信息编辑而成。原始信息源自PeptideDDP.com
FAQ
What is PLATINUM-Truveta?
It is a real-world study by Novo Nordisk comparing semaglutide 2.4 mg with resmetirom in adults with MASH, using de-identified electronic health records from 30 US health systems between June 2021 and March 2026.
Has Novo released the results?
No. The 28 October release only describes who is presenting what and when. The poster (number 2461) is scheduled for 6 November at AASLD.
Does this study prove semaglutide treats MASH?
No. It is an observational comparison without randomization, so it can suggest associations but cannot establish causation. Randomized evidence comes from trials such as ESSENCE.
Is Wegovy approved for MASH?
Wegovy holds FDA accelerated approval for MASH with moderate-to-advanced liver scarring, but not cirrhosis. Continued approval may depend on a confirmatory trial, and a Boxed Warning for possible thyroid tumors applies.
What does this mean for research peptides?
Research peptides are for laboratory use only and are not approved treatments. The AASLD data may shape demand narratives around GLP-1 peptides, but it does not change any product’s regulatory status.